News and Trends 19 Dec 2022
Jacobio’s cancer treatment given breakthrough therapy designations by China CDE
Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the…